Hologic, Inc. (NASDAQ:HOLX), a leading medical technology company specializing in women's health, diagnostics, and medical imaging systems, has been navigating a complex market landscape characterized ...

Explore advancements in women's health through AI, equity, and policy with Mia Keeys of Hologic on I Don’t Care.

Hologic lowered its fiscal 2025 revenue forecast, citing weakness in sales of its breast health products, sending the company's shares down 5% after the bell on Wednesday. The company manufactures and ...

New Mexico Educational Retirement Board cut its position in shares of Hologic, Inc. (NASDAQ:HOLX – Free Report) by 3.5% in ...

We recently published a list of 10 Firms Hit Hard in Thursday’s Trading. In this article, we are going to take a look at ...

Hologic's strength in the molecular diagnostics wing instills optimism among investors. Yet, a dull macroeconomic environment raises concerns.

Louisiana State Employees Retirement System decreased its stake in Hologic, Inc. (NASDAQ:HOLX – Free Report) by 4.6% in the fourth quarter, according to the company in its most recent 13F filing with ...

We now expect low-single-digit decreases in breast health. We remain confident in Hologic's narrow economic moat. We expect to see evidence of the firm's intangible assets and switching costs as ...

The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.

Q1 2025 diagnostics revenue grew 9.1% organically, excluding COVID, supported by strong performance in core women’s health assays ... uncertainties in breast health. Hologic's Q1 2025 results ...